2019 Immune Response RNA 
Broad Institute
FEBRUARY 26, 2025
At the Broad, he decided to focus on myeloid cells, which make up to half of the cells in many brain tumors and can suppress the immune system, preventing immunotherapies from working well. With this approach, the team identified four programs shaping the immune system.
Drug Target Review
APRIL 26, 2023
Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PLOS: DNA Science
MAY 16, 2024
” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013. As soon as the initial RNA genome sequence of the pathogen that would be named SARS-CoV-2 was published, CDC and other organizations began developing diagnostic tests.
Codon
DECEMBER 12, 2024
This includes recipients of a three-million-dollar grant , awarded by the National Science Foundation in 2019, to “design, construct, and safely deploy synthetic mirror cells.” DNA and RNA molecules are also built from exclusively right-handed nucleic acids. 4 As far as we know, right-handed proteins never occur naturally.
The Pharma Data
SEPTEMBER 9, 2020
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.
The Pharma Data
JANUARY 31, 2021
Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.
The Pharma Data
JULY 6, 2021
Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year. a Sanofi Company.
Expert insights. Personalized for you.
132 
Let's personalize your content